Form 4: Processa Pharmaceuticals CFO Acquires Shares

Processa Pharmaceuticals' Chief Financial Officer, Russell Skibsted, has acquired 2,654 shares of common stock.

Summary

• Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, Inc., acquired 2,654 shares of common stock on June 15, 2026.
• The acquisition was made at a price of $2.22 per share.
• Following this transaction, Mr. Skibsted beneficially owns 13,412 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing due to the insider purchase, which can indicate confidence, but it lacks broader financial or strategic information.

Positives

• Insider buying can signal confidence in the company's future prospects.
• The CFO's acquisition of shares indicates a personal investment in the company's performance.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider transactions, such as this share acquisition by a CFO, are closely watched by investors as potential indicators of management's belief in the company's valuation and future performance within the pharmaceutical sector.

Stakeholder Impact

• Shareholders may view this as a positive signal of management's confidence in the company's stock.
• Employees may be encouraged by the CFO's personal investment in the company's success.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, Form 4, Insider Trading, Stock Acquisition, Russell Skibsted, Chief Financial Officer